These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 16968945)

  • 21. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual effect of hypochlorite in the modification of high density lipoproteins.
    Pirillo A; Uboldi P; Catapano AL
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):447-51. PubMed ID: 21094143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H; Pahl MV; Elahimehr R; Vaziri ND
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
    Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA
    J Am Coll Cardiol; 2009 Mar; 53(11):962-71. PubMed ID: 19281927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic management of isolated low high-density lipoprotein syndrome.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins.
    Malle E; Marsche G; Panzenboeck U; Sattler W
    Arch Biochem Biophys; 2006 Jan; 445(2):245-55. PubMed ID: 16171772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidemia in the metabolic syndrome: clinical implications and management.
    Hafidh SA; Lavie CJ; Burns BP; Khan SS; Alpert MA
    Minerva Cardioangiol; 2006 Apr; 54(2):215-27. PubMed ID: 16778753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The double jeopardy of HDL.
    Navab M; Ananthramaiah GM; Reddy ST; Van Lenten BJ; Ansell BJ; Hama S; Hough G; Bachini E; Grijalva VR; Wagner AC; Shaposhnik Z; Fogelman AM
    Ann Med; 2005; 37(3):173-8. PubMed ID: 16019715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The promise of apolipoprotein A-I mimetics.
    Mendez AJ
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Some physiopathologic features of metabolic syndrome].
    Posadas Romero C
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-42-7. PubMed ID: 18938696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-density lipoprotein: a potent inhibitor of inflammation.
    Murphy AJ; Woollard KJ
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):710-8. PubMed ID: 19930423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDL-c is a powerful lipid predictor of cardiovascular diseases.
    Bruckert E; Hansel B
    Int J Clin Pract; 2007 Nov; 61(11):1905-13. PubMed ID: 17655681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients.
    Cho KH; Park SH; Park JE; Kim YO; Choi I; Kim JJ; Kim JR
    Clin Biochem; 2008 Jan; 41(1-2):56-64. PubMed ID: 17996200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vascular inflammation: effect of proatherogenic dyslipidemic trio or quartet].
    Zamaklar M; Lalić K; Lalić N
    Med Pregl; 2009; 62 Suppl 3():37-42. PubMed ID: 19702114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties.
    Kontush A; de Faria EC; Chantepie S; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):526-33. PubMed ID: 14739123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.